GB2597293A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain

USPTO Abstract

A cannabidiol (CBD) preparation for use in the treatment of seizures associated with bilateral cerebral dysgenesis (brain malformation) is provided. The seizures associated with bilateral cerebral dysgenesis may be tonic, atonic and focal seizures with impairment and spasms. The CBD preparation may comprise greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids. The CBD preparation may comprise CBD isolated from cannabis plant material or may be synthetic CBD. The CBD preparation may be used in combination with one or more concomitant anti-epileptic drugs (AED). The one or more concomitant AEDs may be selected form the group consisting of lorazepam, brivaracetam, vigabatrin, zonisamide and clobazam. The dose of CBD may be between 5 mg/kg/day to 50 mg/kg/day. A clinical trial is disclosed wherein a patient diagnosed with bilateral cerebral dysgenesis had a decrease in the amount of tonic, atonic, focal seizures with impairment and spasms after dosing with the CBD preparation and concomitant AEDs.